The civic record
Read. Follow. Verify.Senate Hearing on Prescription Drug Pricing
Record date · January 1, 2019
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Does
The U.S. Senate held a hearing on February 26, 2019, to examine prescription drug pricing in America. The committee heard testimony from the CEOs of seven major pharmaceutical companies regarding industry pricing practices.
This hearing represents a formal legislative inquiry into the factors influencing the cost of prescription drugs, which directly impacts the out-of-pocket expenses for millions of Americans and the national healthcare budget.
Who It Affects
Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.
Pharmaceutical Companies
The executives of these companies were required to provide testimony and respond to inquiries regarding their pricing models.
Patients
The outcome of these hearings may influence future legislation affecting the cost and accessibility of prescription medications.
Key Facts
- The hearing took place on February 26, 2019, in the Dirksen Senate Office Building.
- The session was the second part of a series titled 'Drug Pricing in America: A Prescription for Change'.
- Seven pharmaceutical company executives provided testimony and submitted prepared statements for the record.
- The committee received written communications from various advocacy groups, including AARP, Oxfam America, and Patients for Affordable Drugs Now.
Show all 5 facts
- The hearing was convened by the Senate Committee on Finance to gather information on pharmaceutical pricing strategies.
Frequently Asked Questions
Who testified at this hearing?
What was the purpose of this hearing?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceFull breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
High-Level Industry Scrutiny
The hearing demonstrates a coordinated effort by the Senate Finance Committee to bring the leadership of the entire major pharmaceutical sector into a single forum for questioning.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy60Intensity of disagreement among stakeholders
- Entertainment40Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools